Prediction of cardiovascular adverse events in newly diagnosed multiple myeloma: Development and validation of a risk score prognostic model
BackgroundMultiple myeloma (MM) is the second most common hematological malignancy, and the treatments markedly elevate the survival rate of the patients in recent years. However, the prevalence of cardiovascular adverse events (CVAEs) in MM had been increasing recently. CVAEs in MM patients are an...
Main Authors: | Shuai Yuan, Jie-Yi Zhou, Ben-Zhao Yang, Zhong-Lei Xie, Ting-Jun Zhu, Hui-Xian Hu, Rong Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1043869/full |
Similar Items
-
Multiple Myeloma Patients Undergoing Carfilzomib: Development and Validation of a Risk Score for Cardiovascular Adverse Events Prediction
by: Anna Astarita, et al.
Published: (2021-04-01) -
Cardiovascular Organ Damage and Blood Pressure Levels Predict Adverse Events in Multiple Myeloma Patients Undergoing Carfilzomib Therapy
by: Giulia Bruno, et al.
Published: (2019-05-01) -
Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience
by: Giulia Mingrone, et al.
Published: (2023-02-01) -
Circulating sST2 and prognosis of cardiovascular events in remission of multiple myeloma
by: M. O. Panasenko, et al.
Published: (2022-10-01) -
Pretreatment with Betablockers, a Potential Predictor of Adverse Cardiovascular Events in Takotsubo Syndrome
by: Albert Topf, et al.
Published: (2022-02-01)